High rate of resistance to antiretroviral drugs among HIV-infected prison inmates

Medical Science Monitor

Volumn 9, Issue 6, 2003, Pages

  Gallego, Oscar ^a   Corral, Angélica ^a   De Mendoza, Carmen ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a INSTITUTO DE SALUD CARLOS III   (Spain)

^b NONE   (Spain)

Author keywords

Adherence; Drug resistance; Prison inmates

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA;

ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; GENE MUTATION; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; PREVALENCE; PRISON; RANDOMIZATION; SPAIN;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; ENDOPEPTIDASES; HIV; HIV INFECTIONS; HUMANS; MUTATION; PRISONERS; RETROSPECTIVE STUDIES; RNA, VIRAL; RNA-DIRECTED DNA POLYMERASE; SPAIN; VIRAL LOAD;

EID: 0038506771     PISSN: 12341010     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Baillargcon J, Black S, Pulvino J et al: The disease profile of Texas prison inmates. Ann Epidemiol, 2000; 10: 74-80
2. Braithwaite R, Hammet T, Mayberry R: Prison and AIDS: a public health challenge. San Francisco: Joney-Bass Publishers, 1996
3. Hammett T, Widom R, Epstein J et al: 1994 Update: HIV/AIDS and STDs in correctional facilities. US Department of Justice, National Institute of Justice, and US Department of Health and Human Services. Centers for Disease Control and Prevention, 1994
4. Weisfuse I, Greenberg B, Back S et al: HIV infection among New York City inmates. AIDS, 1991; 5: 1133-1138
5. Case P, Mechan T, Jones TS: Arrest and incarceration of injection drug users for syringe possession in Massachusetts: implications for HIV prevention. J Acquir Immune Defic Syndr, 1998; 18(suppl 1): 71-75
6. Kuritzkes D: Drug resistance testing: time to be used in clinical practice? AIDS Reviews, 1999; 1: 45-50
7. Paredes R, Mocroft A, Kirk O et al: Predictors of virological success and ensuing failure in HIV-positive patients starting highly active antiretroviral therapy in Europe: results from EuroSIDA study. Arch Intern Med 2000; 160: 1123-1132
8. Deeks S, Hecht F, Swanson M et al: HIV-RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy. AIDS, 1999; 13: 35-44
9. Lucas G, Choisson R, Moore R: Highly active antiretroviral therapy in a large urban clinic: risk factors for virologic failure and adverse drug reactions. Ann Intern Med, 1999; 131: 81-87
10. Hirsch M, Brun-Vézinet F, D'Aquila R et al: Antiretroviral drug resistance testing in adult HIV infection. JAMA, 2000; 283: 2417-2426
11. Gómez-Cano M, Rubio A, Puig T et al: Prevalence of genotypic resistance to nucleoside analogues in antiretroviral-naive and anti-retroviral-experienced HIV-infected patients in Spain. AIDS, 1998; 12: 1015-1020
12. Puig T, Pérez-Olmeda M, Rubio A et al: Prevalence of genotypic resistance to nucleoside analogues and protease inhibitors in Spain. AIDS, 2000; 14: 727-732
13. Gallego O, Ruiz L, Vallejo A et al: Changes in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS, 2001; 15: 1894-1896
14. Miró JM, Antela A, Arrizabalaga J et al: Recommendations of GESI-DA/National AIDS Plan on AIDS with respect to antiretroviral treatment in adult patients infected with HIV in the year 2000. Enf Infec Microbiol Clin, 2000; 18: 396-412
15. Spaulding A, Stephenson B, Macalino G et al: HIV in correctional facilities: a review. Clin Infect Dis, 2002; 35: 305-312
16. Verhosfstede C, Fransen K, Marissens D et al. Isolation of HIV-RNA from plasma: evaluation of eight different extraction methods. J Virol Methods, 1996; 60: 155-159
17. Schinazi R, Larder B, Mellors J: Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News, 2000; 8: 65-91
18. IAS-USA Resistance Testing Panel: Antiretroviral resistance mutations (revised April 2001). HIV Clin Trials, 2001; 2: 346-355
19. Winters M, Coolley K, Girard Y et al: A 6-base pair insert in the reverse transcriptase gene of HIV type I confers resistance to multinucleoside inhibitors. J Clin Invest, 1998; 102: 1769-1775
20. Larder B, Bloor S: Analysis of clinical isolates and site-directed mutants reveals the genetic determinants of didanosine resistance. Antiviral Ther, 2001; 6(suppl 1): 38
21. Hertogs K, Bloor S, de Vroey V et al: A novel HIV type 1 reverse transcriptase mutational pattern confers phenotypic lamivudine resistance in the absence of mutation 184V. Antimicrob Agents Chemother, 2000; 44: 568-573
22. Barreiro P, Soriano V, Blanco F et al: Risks and benefits of replacing protease inhibitors by nevirapine in HIV-Infected subjects under long-term successful triple combination therapy. AIDS, 2000; 14: 807-812
23. Joly V, Yeni P: Non-nucleoside reverse transcriptase inhibitors. AIDS Reviews, 1999; 1: 37-44
24. Kavlick M, Wyvill K, Yarchoan R et al: Emergence of multidideoxynucleoside-resistant HIV type I variants, viral sequence variation, and disease progression in patients receiving antretroviral chemotherapy. J Infect Dis, 1998; 177: 1506-1513
25. Briones O, Soriano V, González-Lahoz J: Prevalence of drug-resistant HIV-1 genotypes in heavily pre-treated patients on current virological failure. AIDS, 2000; 14: 1659-1660
26. Yahi N, Tamalet C, Tourrés C et al: Mutation patterns of the RT and protease genes in HIV-1 infected patients undergoing combination therapy: survey of 787 sequences. J Clin Microbiol, 1999; 37: 4009-4016
27. Martín JC, Soriano V, Jiménez-Nácher I et al: Overall trends in CD4 counts and plasma viremia in an urban clinic since the introduction of highly active antiretroviral therapy. Clin Microbiol Infect, 2001; 7: 678-68